BRCA2 and breast carcinoma: With two phenotypically coherent groups of breast cancer patients, which represent the largest collections of BRCA1 and BRCA2 pathologic variant carriers in the world, we were able to identify a single genome-wide significant locus, but were probably underpowered to detect loci with more modest effect sizes.